A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-440 Combination Therapy in Subjects Aged 12 Years and Older with Cystic Fibrosis
A study for patients with Cystic Fibrosis using study drug VX-440
Sponsor: Vertex Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAQ9808
U.S. Govt. ID: NCT02951182
Contact: Claire Keating: 000-000-0000 / ck2132@cumc.columbia.edu
Additional Study Information: The purpose of the ELEVATE CF study is to evaluate an oral investigational medication called VX-440 tosee if it is safe, effective, and well-tolerated when taken alone or with two other oral medications(VX-661 tezacaftor and ivacaftor) in people with cystic fibrosis (CF). This triple combination(TC) is being tested to see if it improves chloride transport (to help treat CF) more than the individualmedications or any dual combinations.
This study is closed
Investigator
Claire Keating, MD
Do You Qualify?
Have you or your child been diagnosed with Cystic Fibrosis (CF)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Claire Keating
ck2132@cumc.columbia.edu
000-000-0000
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE